Short Description: T cell therapies revolutionize cancer care, yet many patients still relapse from T cell exhaustion.Linfa Therapeutics enhances T cell therapies with an immunometabolic platform that boosts persistence and durability. Combining pharmaceutical and nutraceutical strategies, it offers oncology-validated metabolic support to reduce relapses and improve immune resilience. Founded by experienced Penn Medicine researchers, Linfa Bio bridges clinical need and innovation in cancer immunotherapy.
Lessons Learned: We initially believed the core problem was limited T-cell persistence and lack of safe adjuncts, targeting CAR T and hematologic settings. We now understand that inconsistent checkpoint inhibitor responses and reduced T-cell fitness drive unmet need, with clinicians seeking a low-toxicity, oral adjunct that improves durability without adding workflow burden.
Names and Affiliation of Team members:
Ruchi Patel, Alumnus, Perelman School of Medicine, Center for Cellular Immunotherapy
Shan Liu, Postdoctoral Fellow, Perelman School of Medicine, Center for Cellular Immunotherapy
Watch a video of the technology here.